Pharmaceutical industry and patients representatives want to stop restricting Medicare funding for a controversial Alzheimer’s drug. Critics say it should never have been approved.
Facing a host of challenges, Aduhelm’s makers are running an educational campaign directed at consumers who are worried about whether their forgetfulness is a sign of disease.
Scientists may have to wait many years to find out whether Aduhelm is actually effective because the drug was approved using FDA's accelerated pathway.
Prescriptions for a controversial new drug for Alzheimer's could run $56 billion a year, putting a significant financial burden on Medicare, the health insurance for the elderly.
Jose Belardo of Lansing, Kan., spent most of his career in the U.S. Public Health Service. He worked on the front lines of disasters in such places as Haiti, Colombia, Nicaragua and the Dominican Republic.
More than 120 people who care for Alzheimer’s patients held a conference in Wilsonville Wednesday. They learned the first thing families should do when a loved one gets dementia.
Senator Ron Wyden has joined his colleagues, urging the Senate Appropriations Committee to beef up research funding for Alzheimer’s disease.
Currently the NIH spends about $585 million on Alzheimer’s disease and dementia research, compared to $450 million in fiscal year 2011.
Alzheimer's disease ranks among American's most-feared terminal illnesses – and may kill far more people than previously believed, according to research showing Alzheimer's is a factor in deaths such as pneumonia, choking